ocotillol: cardioprotective agent; structure in first source
ID Source | ID |
---|---|
PubMed CID | 3850493 |
MeSH ID | M0515979 |
Synonym |
---|
ocotillol |
(20s,24s)-20,24-epoxydammarane-3beta,25-diol |
Ocotillol is a derivate of pseudoginsenoside-F11, which is an ootillol-type ginsenosides found in American ginseng.
Excerpt | Reference | Relevance |
---|---|---|
"Ocotillol is a derivate of pseudoginsenoside-F11, which is an ocotillol-type ginsenoside found in American ginseng." | ( Ginseng derivative ocotillol enhances neuronal activity through increased glutamate release: a possible mechanism underlying increased spontaneous locomotor activity of mice. Fu, F; Heinbockel, T; Ma, S; Peng, W; Sun, L; Wang, ZJ; Zhu, C, 2011) | 1.42 |
Pre-treatment with ocotillol ameliorated the decreased glutathione level and reduced the cumulated malondialdehyde in the heart tissue.
Excerpt | Reference | Relevance |
---|---|---|
"Pre‑treatment with ocotillol ameliorated the decreased glutathione level and reduced the cumulated malondialdehyde in the heart tissue." | ( Protective effect of ocotillol against doxorubicin‑induced acute and chronic cardiac injury. Fu, F; Fu, X; Kong, L; Li, G; Tang, M; Wang, H; Zhang, J; Zhou, X, 2014) | 1.04 |
"Pre-treatment with ocotillol could attenuate the changes of both SOD and MDA." | ( Cardioprotective effect of ocotillol, a derivate of pseudoginsenoside F11, on myocardial injury induced by isoproterenol in rats. Fu, F; Han, B; Yu, C; Yu, X; Zhu, M, 2007) | 0.96 |
Excerpt | Reference | Relevance |
---|---|---|
" Pharmacokinetic (PK) is a bridge linking the herbal medicines and their pharmacological responses." | ( Pharmacokinetic Characterizations of Ginsenoside Ocotillol, RT5 and F11, the Promising Agents for Alzheimer's Disease from American Ginseng, in Rats and Beagle Dogs. An, Y; Geng, C; Hu, H; Li, R; Li, Y; Li, Z; Liu, Y; Wang, Z; Xu, F; Zhang, B; Zhao, C, 2019) | 0.77 |
" The values of Cmax and AUC(0-t) indicated ocotillol type ginsenosides had low systemic exposure and poor absorption into blood." | ( Pharmacokinetic Characterizations of Ginsenoside Ocotillol, RT5 and F11, the Promising Agents for Alzheimer's Disease from American Ginseng, in Rats and Beagle Dogs. An, Y; Geng, C; Hu, H; Li, R; Li, Y; Li, Z; Liu, Y; Wang, Z; Xu, F; Zhang, B; Zhao, C, 2019) | 1.03 |
Excerpt | Reference | Relevance |
---|---|---|
" Fortunately, its bioavailability can be improved by means of pharmaceutical strategies, including nanoparticles, liposomes, emulsions, micelles, etc." | ( Biopharmaceutical characters and bioavailability improving strategies of ginsenosides. Cai, Q; Chen, Q; He, H; Liu, D; Liu, Y; Miao, L; Pan, W; Tang, X; Xue, B; Yang, C; Yin, T; Zhang, Y; Zhou, L, 2018) | 0.48 |
Excerpt | Relevance | Reference |
---|---|---|
" However, it is severely restricted by its associated dose‑dependent cardiotoxicity, which may be attenuated by decreasing the cumulative dosage via combining with a non‑toxic 'sensitizer'." | ( Protective effect of ocotillol against doxorubicin‑induced acute and chronic cardiac injury. Fu, F; Fu, X; Kong, L; Li, G; Tang, M; Wang, H; Zhang, J; Zhou, X, 2014) | 0.72 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (2.94) | 29.6817 |
2010's | 18 (52.94) | 24.3611 |
2020's | 15 (44.12) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.19) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (8.82%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 31 (91.18%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |